Table 1.

Clinical characteristics.

Variable	Groups
Sex	female: 105 (29.2%); male: 255 (70.8%)
Age at diagnosis (yr)	mean: 62.47; min: 15; max: 86
T category	pT1: 11 (3.1%); pT2: 40 (11.1%); pT3: 219 (60.8%); pT4: 89 (24.7%)
N category	N0: 103 (28.6%); N1: 178 (49.4%); N2: 78 (21.7%)
M category	M0: 228 (63.3%); M1: 132 (36.7%)
Stage	UICC I: 24 (6.7%); UICC II: 46 (12.8%); UICC III: 157 (43.6%); UICC IV: 132 (36.7%)
Histological grading	G1: 19 (5.3%); G2: 274 (76.1%); G3: 57 (15.8%)
Radiation dose (Gy)	50.4: 344 (95.6%); >50.4: 16 (4.4%)
Chemotherapy	FOLFOX: 268 (74.4%); FOLFIRI: 18 (5%); FOLFOXIRI: 10 (2.8%); 5-FU solo: 52 (14.4%); XELOX: 8 (2.2%)
Surgery	Yes: 331 (91.9%); No: 29 (8.1%)